Dana-Farber Cancer Institute | Strategic Alliance Partners

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Alicia Morgans, MD, MPH, discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer.

Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Sara M. Tolaney, MD, MPH, highlights the FDA approval of sacituzumab govitecan plus pembrolizumab for first-line TNBC management.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, discusses an analysis of depth of response in HER2-positive advanced/metastatic breast cancer treated with T-DXd plus pertuzumab.

Toni Choueiri, MD, discusses the significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.

Ficerafusp alfa plus pembrolizumab generated a 54% ORR and 21.7-month median DOR in first-line HPV-negative recurrent or metastatic HNSCC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

Magnolia Contreras, MSW, MBA, of Dana-Farber Cancer Institute, was honored with The Lemuel Shattuck Award for Significant Contributions to Public Health Practice.

A small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Rising rates of early-onset cancers have prompted shifts in management strategies and new research avenues.

Drs Matulonis and Shea explore the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and ADCs across disease settings.

Studies in pancreatic and prostate cancer selected for ASCO’s Plenary Program.

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

Stephanie A Berg, DO, discusses frequent UTIs in women and when bladder cancer referral may be appropriate.

A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.

Bradley McGregor, MD, discusses the rationale of the STRIKE trial of tivozanib plus pembrolizumab in RCC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.